BiotechTube

Placebo + ABT-494

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Mar 17, 2015 → Aug 3, 2017

NCT ID
NCT02365649

About Placebo + ABT-494

Placebo + ABT-494 is a phase 2 stage product being developed by AbbVie for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02365649. Target conditions include Crohn's Disease.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved
✅Cimzia + MesalamineUCBApproved
✅Certolizumab PegolUCBApproved
✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02365649Phase 2Completed

Competing Products

20 competing products in Crohn's Disease

See all competitors
ProductCompanyStageHype Score
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
CP-461Astellas PharmaPhase 2
35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44
Matching Placebo for Upadacitinib + UpadacitinibAbbViePhase 3
40
Adalimumab + PlaceboAbbViePhase 3
40
Upadacitinib + Placebo for UpadacitinibAbbViePhase 3
40
ABT-494AbbViePhase 2
35
Risankizumab + ComparatorAbbViePre-clinical
33
placebo for risankizumab + risankizumab IV + risankizumab SCAbbViePhase 3
40